Amid the ongoing changes in the business environment, including the growing size of plants, the increasing sophistication in equipment and demands for earlier project completion, the Chiyoda Group has been continuously working to ensure customer satisfaction through engineering of outstanding quality.
Chiyoda Philippines Corporation (CPh) was awarded a project (STAR TREC Project） by the Philippines Shell Petroleum Corporation （PSPC) to modernize a refinery. The project was the first medium-sized oil refining project in Asia for CPh accomplished by EPCm. CPh handled all aspects of the project from the basic design to EPCm while collaborating closely with the Chiyoda Group, and successfully completed the project in 2015.
In order to execute the project efficiently, CPh put together a team made up of project team members and engineers who worked closely to resolve any issues, and communicated with customers in a timely manner. CPh assigned local engineers with a strong sense of responsibility and pride, and who were committed to the development of the country’s infrastructure. These factors were key to the successful completion of the project.
CPh worked closely with experts from the Chiyoda Group to implement its ‘C-Safe’ safety management system. As a result of the strong partnership, there were no accidents during the construction period of 23 months (2.7 million hours).
The project is testament to the ongoing strategy of strengthening regional bases by improving the execution skills and competitiveness of local offices through strong partnerships and teamwork.
Photo of Pilipinas Shell Petroleum Corporation
JKC Australia is a joint venture formed by JGC, KBR and Chiyoda. On 13 January 2012, all three companies entered into an EPC contract for the Engineering, Procurement, Construction and Commissioning of an onshore LNG Plant on the the Ichthys LNG Project, which is based in Darwin, Australia. INPEX Operations are the EPC’s client, which expects to start the supply of gas in the third quarter of 2017 (July – September). The project is one of the world’s largest LNG developments, which involves gas from the Ichthys Field in the Browse Basin off north-west Australia being exported to the onshore processing facilities in Darwin via an 890 km pipeline.
The primary goal is to create a world class, number one Incident Injury Free Project.
•Positive two-way communication with work groups, between subcontractors across all levels
•Empowerment of workforce and visible leadership on the ground
•Creative innovation and enjoyment of the journey
The takeaway for every JKC employee is to keep a focus on generating strong relationships across the project.
In addition, the IGL LNG project required high sustainability for the surrounding natural environment of inhabitant.
It is achieved by introducing Enclosed Ground Flare Package which is equipped with state-of-the-art air supply technology to maintain adequate conditions for the combustion of waste gas and contributes to a high smokeless performance.
The Ichthys LNG project will produce 8.9 million tons of LNG per year, equivalent to over 10% of Japan’s annual LNG consumption. Approximately 5.7 million tons of the LNG will be shipped to customers in Japan annually.
I’ROM Group Co., Ltd. (I’ROM Group) will build a GMP facility to manufacture regenerative medicine and gene therapy drugs based on the Sendai virus (SeV) vector technology which its subsidiary, ID Pharma Co., Ltd. (ID Pharma) holds as a platform technology. The facility will be located at the site of ID Pharma’s headquarters in Tsukuba, Ibaraki Prefecture.
ID Pharma has obtained patents on the iPS cell generation technology using Sendai virus (SeV) vector, mainly in Japan, Europe and America, and the Company has developed the iPS cell generation kit "CytoTune®- iPS" based on that technology. While the kit has commercially sold well all over the world with high acclaim from the users, there has been demands for production and supplies of the kit for clinical use with ID Pharma’s advanced technology.
ID Pharma Co., Ltd.
“iPS cell generation kit”
The vector, meaning "courier or carrier", is a material that has the function to convey therapeutic genes to specific organs and tissues, and then introduce the therapeutic genes into target cells effectively.
As Sendai virus (SeV) vector does not damage a chromosome at the time of gene transfer, it is said that a cell is at low risk of malignant alteration. This feature is very important to induce iPS cell, and leads to the big development of regenerative medicine and the gene therapy. To construct the GMP facility for Sendai virus (SeV) vector in compliance with GMP, the Chiyoda Group provides high quality technology through its engineering services.
As the most reliable company (Reliability No.1 Company) to be trusted and ensure safety, we continue to aim at the sustainable development of society with our customers.
ID Pharma Co., Ltd.
Comments from the Client
The I’ROM Group has been working on advanced medicinal treatment fields such as Gene Therapy, Cell Therapy , Regenerative Medicine.
This time, ID Pharma, a Group company of the I’ROM Group, decided to build a Sendai virus (SeV) vector GMP facility at our head office and laboratory in Tsukuba.
The Sendai virus (SeV) vector technology is not only a powerful tool for the development of iPS cell based regenerative medicine, but also can be applied to gene therapy drugs, genetic vaccines and other products.
The Chiyoda Group engaged in the construction of this new production facility from the design phase and offered a compact facility of high quality.
I think that Chiyoda Group’s capability in making high level suggestions about the design and functionality comes from its considerable project experience and achievements in the advanced medicinal treatment fields, not to mention its ability to make the facilities comply with GMP standards. In a limited time, the Chiyoda Group, maintaining close communications, has reflected our thoughts, suggestions and advice with flexible ideas. I think this attitude has enhanced the confidence in each other, and also enabled the sharing of our technical capabilities. In addition, they have responded quickly to the changes and demands we made in the various stages. I also think that the attitude of sincerely following up has led to realizing the smooth construction.
Now, we are aiming to complete the construction of the GMP facility with a priority on safety in collaboration with the Chiyoda Group in November 2016.
With a sense of "speed", the most important in the tip medical field, we will expand the use of the core technology of the I’ROM Group into the fields of not only iPS cell, but also Gene Therapy with the engineering of Chiyoda Group to start the supply of Sendai virus (SeV) vector, and contribute to further advancing medicinal treatment.